AAOpt 2024: Advancing management of meibomian gland dysfunction

At the 2024 American Academy of Optometry meeting in Indianapolis, Indiana, Mila Ioussifova, OD, CNS, FAAO, FOWNS, delivered an insightful presentation on elevating the management of meibomian gland dysfunction (MGD). Collaborating with fellow ocular surface specialist Rana Taji, OD, MSc, FAAO, Ioussifova focused on the array of advanced treatments available for dry eye disease—a condition increasingly prevalent in today’s patient population.

During their session, which is entitled "From expressions to probing - Take your MGD management to the next level," Ioussifova and Taji explored various treatment modalities, including thermal therapies, radiofrequency, and light-based treatments such as Intense Pulsed Light (IPL) and low-level light therapy. They emphasized the importance of understanding the underlying pathophysiology of MGD to tailor treatment choices effectively. With numerous options available, it can be daunting for practitioners to determine the best course of action. The presenters aimed to demystify these choices, providing clear guidance on when to employ specific treatments based on individual patient cases.

One of the standout elements of the presentation was a discussion on meibomian gland probing—an often underutilized procedure in dry eye management. Ioussifova highlighted the benefits of this technique, sharing practical tips and techniques to encourage more optometrists to incorporate probing into their practices. This hands-on approach aims to not only improve patient outcomes but also enhance the overall understanding of MGD treatment.

In addressing the complexities of dry eye cases, Ioussifova shared crucial pearls of wisdom for practitioners. She noted the importance of recognizing that not all patients are ideal candidates for every new technology. Understanding the different types of MGD and their root causes is essential for successful treatment outcomes. Additionally, she stressed the value of combining various treatment modalities to achieve optimal results.

Key takeaways from the session included the recognition that dry eye is becoming increasingly common, underscoring the need for comprehensive screening practices. Ioussifova urged optometrists to routinely assess patients for MGD, as it often develops years before symptoms manifest. By integrating advanced treatments early, practitioners can effectively manage the disease and improve patient quality of life.

In conclusion, Ioussifova's presentation provided valuable insights into advancing the management of MGD. By understanding the disease better, leveraging a variety of treatment options, and emphasizing proactive patient care, optometrists can play a crucial role in alleviating the burdens of dry eye disease. As Ioussifova aptly noted, looking at dry eye as a legitimate ocular disease is essential for enhancing patient outcomes in our increasingly technology-driven practice environment.